explore -WSS

explore

author：comprehensive 2025-09-03 15:17:19 - browse：9

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Innovation in antibiotics is ailing. 'Brain drain' may kill it

WSS

STAT wants to know your pick for a great summer read or listen

Letters to First Opinion on caregivers, digital health, and more

Shifting the focus from loneliness to social health

Cord blood banking comes at a high cost to babies

UnitedHealth CEO's Medicaid comments send insurer stocks diving

UnitedHealth CEO's Medicaid comments send insurer stocks diving

knowledge

explore

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The most pressing bird flu mysteries scientists want answered

Virginia high school admissions case could be legal follow

Finland to offer bird flu vaccine to select groups of people, a possible global first

The cancer drug shortage isn’t new — and neither are the solutions

Woman returns to dialysis after doctors remove transplanted pig kidney

Peter Hotez and the public health issue of online harassment

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Activists slam private health insurers over coverage restrictions

HIV drugs protect against transmission, even in unprotected sex

Wikipedia

Letters to First Opinion on caregivers, digital health, and more

With trial win, GSK could get blood cancer drug back on market

Fight over Supreme Court dialysis ruling puts kidney patients at risk

ASCO Daily Recap: CAR

Senators tussle over abortion against the backdrop of a presidential campaign

Congress needs to close a vaccine

hotspot

focus

Wikipedia

leisure time